Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology

Abstract

Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups.

Keywords: Consensus document; Documento de consenso; Inhibidores PCSK9; Lipids and ischemic heart disease; Lípidos en enfermedad coronaria; PCSK9 inhibitors.